Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases

doi:10.5306/wjco.v16.i8.107009

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (23)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=23

Aug 24, 2025 (publication date) through Aug 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Aug 24, 2025; 16(8): 107009
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.107009

Table 2 Treatment response analysis, n (%)

Treatment response	Concurrent ICI, n = 54	Consolidation ICI, n = 62	P value
CR	12	11
PR	24	26
SD	13	18
PD	5	7
ORR	36 (66.7)	37 (59.7)	0.389

CR: Complete response; ICI: Immune checkpoint inhibitor; PR: Partial response; SD: Stable response; PD: Progressive disease; ORR: Objective response rate.

Citation: Liu XJ, Ge H, Yuan CL. Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases. World J Clin Oncol 2025; 16(8): 107009
URL: https://www.wjgnet.com/2218-4333/full/v16/i8/107009.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i8.107009